"10.1371_journal.pone.0070430","plos one","2013-07-31T00:00:00Z","Rebekka Müller; Kristine Misund; Toril Holien; Siri Bachke; Karin M Gilljam; Thea K Våtsveen; Torstein B Rø; Emanuele Bellacchio; Anders Sundan; Marit Otterlei","Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; APIM Therapeutics AS, Trondheim, Norway; Research Laboratories, Bambino Gesú Childreńs Hospital, IRCCS, Rome, Italy; K.G. Jebsen Center for Myeloma Research, Trondheim, Norway","Conceived and designed the experiments: RM KM TH AS TR EB MO. Performed the experiments: RM KM TH SB KG MO. Analyzed the data: RM KM TH MO. Contributed reagents/materials/analysis tools: TV. Wrote the paper: RM TH KM MO.","The authors have the following interests. APIM Therapeutics is a spin-off company of the Norwegian University of Science and Technology, and was a co-funder for this study. Professor Marit Otterlei is an inventor, minority shareholder and CSO in this company. Patent application no: PCT/GB2009/000489, “New PCNA interacting motif”, was filed on February 20 2009. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2013","07","Rebekka Müller","RM",10,TRUE,7,6,4,4,TRUE,TRUE,FALSE,0,NA,FALSE
